Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
NCT05220098Phase 2Terminated
- Sponsor
- Takeda
- Start
- Apr 2022
- Primary completion
- Jul 2025
- Modality
- Small Molecules, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of TAK-280 in cancer, sponsored by Takeda. Started Apr 2022; status: terminated.
02
Drugs
TAK-280
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05220098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05220098.